

1 **A plasma proteomic signature links secretome of senescent monocytes to aging- and**  
2 **obesity-related clinical outcomes in humans**

3

4 Bradley Olinger\*<sup>1,2</sup>, Reema Banarjee\*<sup>1</sup>, Amit Dey<sup>1</sup>, Dimitrios Tsitsipatis<sup>4</sup>, Toshiko Tanaka<sup>1</sup>, Anjana  
5 Ram<sup>1</sup>, Thedoe Nyunt<sup>1</sup>, Gulzar Daya<sup>3</sup>, Zhongsheng Peng<sup>3</sup>, Linna Cui<sup>1</sup>, Julián Candia<sup>1</sup>, Eleanor M.  
6 Simonsick<sup>1</sup>, Myriam Gorospe<sup>4</sup>, Keenan A. Walker<sup>3</sup>, Luigi Ferrucci<sup>1</sup>, Nathan Basisty<sup>1</sup>

7 \*Contributed equally

8

9 <sup>1</sup>Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland, USA.

10 <sup>2</sup>Department of Biology, Johns Hopkins University, Baltimore, Maryland, USA

11 <sup>3</sup>Laboratory of Behavioral Neuroscience, National Institute on Aging, NIH, Baltimore, Maryland,  
12 USA

13 <sup>4</sup>Laboratory of Genetics and Genomics, National Institute on Aging, NIH, Baltimore, Maryland,  
14 USA

15

16

17

18 **Correspondence:**

19 **Nathan Basisty, PhD**

20 **[nathan.basisty@nih.gov](mailto:nathan.basisty@nih.gov)**

21

22

23

24 **Abstract**

25 Cellular senescence increases with age and contributes to age-related declines and pathologies.  
26 We identified circulating biomarkers of senescence associated with diverse clinical traits in  
27 humans to facilitate future non-invasive assessment of individual senescence burden and efficacy  
28 testing of novel senotherapeutics. Using a novel nanoparticle-based proteomic workflow, we  
29 profiled the senescence-associated secretory phenotype (SASP) in monocytes and examined  
30 these proteins in plasma samples (N = 1060) from the Baltimore Longitudinal Study of Aging  
31 (BLSA). Machine learning models trained on monocyte SASP associated with several age-related  
32 phenotypes in a test cohort, including body fat composition, blood lipids, inflammation, and  
33 mobility-related traits, among others. Notably, a subset of SASP-based predictions, including a  
34 'high impact' SASP panel that predicts age- and obesity-related clinical traits, were validated in  
35 InCHIANTI, an independent aging cohort. These results demonstrate the clinical relevance of the  
36 circulating SASP and identify relevant biomarkers of senescence that could inform future clinical  
37 studies.

## 38 Introduction

39  
40 Cellular senescence, a hallmark of aging<sup>1</sup>, is a state of permanent cell-cycle arrest in response to  
41 a variety of sublethal stresses, such as DNA damage, oxidative stress, metabolic imbalance, and  
42 telomere erosion<sup>2</sup>. Despite being in replication arrest, senescent cells remain metabolically active  
43 and secrete a plethora of proteins and other biomolecules, including cytokines, chemokines,  
44 metalloproteases, and growth factors, collectively known as the senescence-associated secretory  
45 phenotype (SASP)<sup>3</sup>. With increasing age, senescent cells accumulate in various tissues<sup>1</sup> and, at  
46 least partially via the SASP, contribute to diverse age-related pathologies, including cognitive  
47 decline<sup>4-7</sup>, cardiovascular disease<sup>8</sup>, and immune dysfunction<sup>9-11</sup>, among others<sup>12-14</sup>. Importantly,  
48 selective elimination of senescent cells and modulation of the SASP by senotherapeutic  
49 interventions are effective strategies to improve age-associated pathologies in preclinical  
50 models<sup>7,15,16</sup>. Thus, developing methods to identify and eliminate senescent cells in humans is a  
51 promising goal for improving healthspan.

52 In recent years, senescence of immune cells, including monocytes, have been implicated  
53 as a potentially key driver of age-related pathologies. Senescence of immune cells increases with  
54 age and is thought to contribute to an age-related increase of sterile inflammation —  
55 “inflammaging” — and higher susceptibility to infectious diseases<sup>17</sup>. Additionally, higher levels of  
56 senescence in the immune system drive systemic aging and propagate senescence in solid  
57 organs, such as the liver, kidney and lung<sup>18</sup>. There is emerging evidence that senescent  
58 monocytes accumulate *in vivo* in humans. These circulating immune cells form up to 10% of the  
59 total white blood cells and are involved in pathogen recognition via Toll-like receptors (TLRs) and  
60 regulation of inflammation. A proinflammatory phenotype of monocytes has been attributed to  
61 senescence in the elderly<sup>19</sup>. Notably, circulating monocytes express a senescence-like signature  
62 *in vivo* in subjects with severe COVID, and SASP from these monocytes was associated with  
63 increased severity of the infection, suggesting an important role of senescent monocytes in  
64 mediating systemic inflammation in COVID patients<sup>20</sup>. Moreover, monocytes are promising  
65 sources of biomarkers due to their abundance in blood. Despite their potential involvement in  
66 inflammaging and biomarker potential, the role of monocyte senescence-associated proteins in  
67 aging and their potential as clinical biomarkers are poorly characterized.

68 Quantifying circulating biomarkers of senescence holds clinical potential for identifying  
69 outcomes tied to senescence, enabling non-invasive determination of individual senescence  
70 burden for risk stratification, and tracking the effectiveness of senotherapeutics in clinical  
71 trials<sup>21,22</sup>. In recent years, high-throughput proteomic studies have quantitatively profiled

72 senescence-associated proteins in circulation and demonstrated their associations with diverse  
73 aging-related outcomes in humans<sup>21-23</sup>, including mortality, multimorbidity, strength and mobility.  
74 These studies leveraged human cohorts, such as InCHIANTI (Invecchiare in Chianti), BLSA  
75 (Baltimore Longitudinal Study of Aging), GESTALT (Genetic and Epigenetic Signatures of  
76 Translational Aging Laboratory Testing), Lifestyle Interventions for Elders (LIFE), and others<sup>24-30</sup>.  
77 However, no biomarker studies to date have comprehensively characterized the monocyte-  
78 specific SASP and evaluated its clinical utility as circulating biomarkers in humans.

79 The primary goal of this study is to comprehensively profile the monocyte SASP in serum-  
80 supplemented culture conditions and evaluate its clinical utility as a circulating biomarker in  
81 humans. We adopted a novel automated nanoparticle-based workflow previously leveraged for  
82 analysis of plasma<sup>31</sup> that overcomes the challenges associated with mass spectrometry (MS)-  
83 based profiling of serum-supplemented medium. Thus, we completed the first comprehensive MS  
84 analysis of SASP that is not confounded by serum-free culture conditions, which are widely used  
85 for MS-based quantification of SASP from cell-culture experiments<sup>32</sup>. Moreover, we evaluated the  
86 senescent monocyte signatures in the plasma proteome of the BSLA study. We identified  
87 signatures of SASP, including a high-impact panel, that predict age-related and obesity-  
88 associated clinical traits in a test cohort. Remarkably, SASP-based clinical trait associations were  
89 replicated in InCHIANTI, an independent aging study.

90

## 91 **Results**

92

### 93 **Optimization of senescence in monocytes and development of a biomarker discovery** 94 **pipeline**

95 To develop a rigorously validated model of cellular senescence in monocytes (**Fig. 1a**), senescent  
96 THP-1 monocyte cells were generated with multiple protocols, and an optimal method was  
97 selected, based on the expression of a combination of senescence biomarkers and cell viability.  
98 Senescence was induced in THP-1 monocytes with varying doses of gamma irradiation (IR) and  
99 assessed at various time points after IR. To test viability and proliferation, THP-1 cells in complete  
100 medium were exposed to different doses of IR (5, 7.5 and 10 Gy) and cell viability measurements  
101 at 24-h intervals up to 13 days confirmed that these doses are not lethal (**Fig. S1a**). However, cell  
102 proliferation was inhibited after exposure to 7.5 and 10 Gy as seen by reduced incorporation of  
103 5-ethynyl-2'-deoxyuridine (Edu) in the treated cells (**Fig. 2a-b; Fig S1g**). Further, the expression  
104 levels of a panel of senescence marker mRNAs (*GDF15* mRNA, *CDKN2A* (*p16*) mRNA and  
105 *CDKN1A* (*p21*) mRNA) and mRNAs encoding SASP factors (e.g., *IL1A* and *IL6* mRNAs) were

106 significantly higher in IR-treated cells than proliferating controls (**Fig. 2c; Fig. S1b-e**). Elevated  
107 levels of SPiDER  $\beta$ -gal in IR-treated cells further confirmed the stable induction of senescence 7  
108 days after exposure to 7.5 Gy (**Fig. 2d; Fig. S1f**). Given the stable cell-cycle arrest, viability, and  
109 expression of senescence-associated mRNAs at this dose, we used 7.5 Gy IR radiation and 7  
110 days in culture in all later experiments.

111

## 112 **Identification of the monocyte SASP in standard culture conditions**

113 MS-based proteomic analysis is notoriously challenging in serum-supplemented cell-culture  
114 conditions due to the highly dynamic range of serum proteins<sup>33</sup>. In standard cell-culture conditions,  
115 fetal bovine serum (FBS) introduces a high concentration of exogenous proteins that hinder the  
116 detection of endogenously secreted proteins from cultured cells at lower levels. To overcome  
117 these challenges, we applied a novel proteomic platform that was previously used to analyze  
118 blood samples<sup>34-36</sup>. An automated robotic platform utilizes nanoparticle-based enrichment of  
119 protein coronas for a deep and unbiased identification of proteins in high-dynamic-range samples  
120 (Proteograph™ XT Assay, Redwood City, CA)<sup>31</sup>. Reasoning that serum-supplemented medium  
121 faces essentially the same challenges as serum itself, we applied this instrumentation in  
122 combination with a multi-species proteomic analysis (bovine + human) to comprehensively and  
123 quantitatively profile the monocyte SASP (**Fig. 1b**). Briefly, data independent acquisition (DIA)  
124 MS-based proteomics was conducted on the secretomes of senescent and non-senescent  
125 monocytes processed with the nanoparticle workflow (n=14), as well as matched samples  
126 processed with no nanoparticle separation (n=6) to compare with a standard workflow. Using the  
127 standard workflow, 3,935 proteins (24,875 peptides) were identified, and weak separation  
128 between senescent and non-senescent secretome was evident by principal component analysis  
129 due to interference from the supplemented bovine proteins (**Fig. 3a**). In contrast, the nanoparticle-  
130 based workflow enabled the detection of 10,089 proteins (96,511 peptides) and identified  
131 differences in the two secretomes as evident in principal component analysis (**Fig. 3b-c**); these  
132 values represented a significant improvement over our reported secretome studies<sup>30</sup>. Additionally,  
133 even though protein expression was positively correlated on the peptide and protein level between  
134 neat and nanoparticle-processed samples (**Fig. S2a,b**), the reproducibility of protein  
135 measurements was improved after processing (**Fig. S2c**). Any peptides that matched bovine  
136 proteins, as well as those shared between human and bovine, were removed, and the remaining  
137 6,161 human proteins were compared between senescent and non-senescent secretomes.  
138 Senescent secretomes had 3,413 increased proteins and 180 decreased proteins, compared to  
139 controls (**Fig. 3d**). Gene Ontology analysis of the top 200 upregulated proteins indicated

140 enrichment of biological processes such as response to interferons, a known senescence-  
141 associated pathway, and transmembrane transport (**Fig. 3e**). Furthermore, a comparison of the  
142 monocyte SASP with that of fibroblasts using the SASP Atlas (<http://www.saspatlas.com/>)<sup>30</sup>  
143 revealed 237 proteins, or 43% of the fibroblast SASP proteome, overlapped with the monocyte  
144 SASP proteome (**Fig. 3f**). Ontology analysis reveals that these proteins are involved in multiple  
145 biological processes, including cellular detoxification and regulation of apoptotic processes and  
146 oxidative stress–induced pathways (**Fig. 3g**). Interestingly, these pathways were also reported  
147 among the fibroblast core SASP<sup>30</sup>. Full proteomic replicate data, quantification, and statistics are  
148 available in **Table S1**.

149

### 150 **The senescent monocyte secretome is detectable in circulating plasma in BLSA**

151 The clinical associations of the monocyte SASP in circulation were examined in the BLSA. This  
152 longitudinal study used multiple biochemical and clinical assessments to examine the  
153 physiological and functional changes associated with healthy aging. BLSA participant  
154 characteristics are displayed in **Table 1**. This analysis utilized the plasma proteomic data from  
155 the BLSA that had been acquired using the 7K SOMAscan Assay (Somalogic Inc., Boulder, CO),  
156 which performs 7,288 protein measurements<sup>37,38</sup>. Among the SomaScan protein panel, 1550  
157 monocyte SASP proteins were measured in the BLSA (**Fig. 4a, Table S2**). To evaluate the age-  
158 associated clinical relevance of the monocyte SASP, we used Spearman correlation to identify  
159 only the components of the monocyte SASP that were increasing in circulation across the lifespan  
160 in the BLSA. Of the monocyte SASP in circulating plasma, 308 proteins were upregulated and  
161 also positively associated with age (**Table S2**). To evaluate clinical traits associated with SASP  
162 regardless of covariate such as age, we utilized the full SASP panel (1550 proteins) including  
163 covariates such as age, sex, and race in downstream clinical trait associations.

164

### 165 **Monocyte SASP signatures predict mobility and obesity-associated clinical outcomes**

166 To identify the most clinically relevant monocyte SASPs without model overfitting, elastic net  
167 modeling was performed for unbiased feature selection of proteins that associate with a diverse  
168 set of clinical outcomes, while controlling for age, sex, race, and kidney function as model  
169 covariates. Clinically relevant SASP factors were identified for a panel of clinical traits, including  
170 mobility, inflammation, body composition, and metabolism-related measurements in the BLSA  
171 (**Fig. 4b**). For each trait, a different subset and number of biologically relevant proteins were  
172 identified and subsequently referred to as elastic net-selected proteins (ENSPs) (**Fig. 4c**). One  
173 established metric for validating biomarker candidates for clinical traits is their out-of-sample

174 predictive accuracy. This was examined in a cohort of 1,330 subjects from the BLSA, split into a  
175 training dataset (80%) and test dataset (20%). Elastic net models that include ENSPs and  
176 covariates were trained using the training dataset and used to predict clinical traits in the testing  
177 dataset. These Elastic Net models showed significant correlation between observed and  
178 predicted values (FDR < 0.05) (**Fig. 4b**) for all clinical traits, and showed highest out-of-sample  
179 trait prediction potential for Triglycerides (cor. = 0.8447), HDL (cor. = 0.8343), waist size (cor. =  
180 0.7844), LDL (cor. = 0.7508), BMI (cor. = 0.6851), and 400-meter walking pace (cor. = 0.7085).  
181 (**Fig. 4b**), suggesting that these subsets of monocyte SASP are implicated in these clinical traits.  
182 Elastic net models also outperformed a model using covariates alone (e.g., age, sex, race and  
183 kidney function) in predicting obesity (**Fig. 4d**). After adjusting for covariates, the size of the  
184 regression coefficient for the SASP proteins in the elastic net model did not change substantially  
185 (**Fig. S3a**), suggesting that ENSPs are not simply demonstrating association with clinical traits  
186 due to their association with age and might have age-independent clinical implications.

187

#### 188 **Association of SASP signatures with body fat depots and percentages**

189 Because ENSPs had strikingly high predictive potential of clinical traits related to BMI and waist  
190 size, we explored whether these associations were driven by fat in specific fat depots in the body.  
191 We examined senescence markers and their predictive potential using elastic net modeling of  
192 whole-body computed tomography (CT) and dual x-ray absorptiometry scans of the BLSA  
193 participants. These measurements were used to quantify body fat content at various regions  
194 across the body, including subcutaneous fat in the limbs and abdomen, visceral fat, and  
195 intramuscular fat depots. A significant out-of-sample predictive potential was found across all  
196 body fat measures (**Fig. 5a**), utilizing ENSPs that were selected for each trait (**Fig. 5b**).  
197 Correlations between ENSPs and body fat were relatively high across different fat depots, ranging  
198 from 0.5074 to 0.7473, with the highest correlation in trunk fat and the lowest in abdominal  
199 subcutaneous fat. Moreover, total-body fat percentage was most strongly associated with  
200 senescence signatures (Spearman Cor. = 0.7913) than any individual fat depot (**Fig. 5a,d**).  
201 Because fat percentage is adjusted for overall body size, these data suggest that overall  
202 proportion of body fat, rather than the size of any specific fat depot, is associated with a monocyte  
203 senescence-associated protein signature. ENSPs were also used to predict fat percent in an  
204 independent test cohort and outperformed a covariate-only (age, sex, race, eGFR) model when  
205 predicting fat percent-based obesity (**Fig. 5c**), suggesting that ENSPs have age and covariate  
206 independent predictive potential.

207

## 208 **Validation of senescence signatures in an independent aging cohort**

209 We next sought to further validate the role of monocyte SASPs in multiple phenotypes. We  
210 performed a cross-validation analysis using plasma proteomic data from BLSA and InCHIANTI  
211 (demographics and clinical traits summarized in **Table S3**), a population-based study of older  
212 individuals living in the Chianti geographic area of Italy, which was assessed using the 1.3k  
213 SomaScan assay, an earlier version of the assay containing subset of the total protein  
214 measurements in BLSA. We identified 220 monocyte SASP candidates detected in both cohorts  
215 that were selected for further testing for clinical trait associations. ENSPs were identified for  
216 several clinical traits in both BLSA (**Fig. S4a**) and InCHIANTI (**Fig. S4b**). ENSPs identified in both  
217 cohorts were used to train linear models used for cross-validation. These linear models, when  
218 trained on the BLSA cohort, significantly predicted several clinical traits in InCHIANTI (**Fig. S4c**),  
219 and when trained on the InCHIANTI cohort, significantly predicted many clinical traits in the BLSA  
220 (**Fig. S4d**). These overlapping ENSP effectively cross-validated in both directions for several  
221 clinical traits including BMI, triglycerides, and walking pace, among others in BLSA and  
222 InCHIANTI (**Fig. 6a**), indicating a robust ability of these proteins to predict clinical traits.  
223 Additionally, a binomial model trained on overlapping ENSPs in BLSA predicted obesity in  
224 InCHIANTI better than an age and sex-only model (**Fig. 6b**). The cross-validation potential of  
225 ENSPs for a subset of clinical traits, such as BMI, blood pressure, triglycerides, and walking pace,  
226 in geographically and genetically distinct human cohorts demonstrates their robust clinical  
227 relevance.

228

## 229 **A select senescence panel robustly predicts aging- and obesity-related outcomes**

230 To explore whether a parsimonious subset of the total SASP would capture most of the  
231 association between SASP proteins and multiple clinical traits, we prioritized and selected a  
232 smaller set of proteins based on their associations with multiple traits and relative importance.  
233 Though a different subset of SASPs was selected for each trait, consistent with previous  
234 reports<sup>39,40</sup>, notable features (proteins) were selected via elastic net modeling in several traits of  
235 a fourteen-trait panel. Ranking the ENSPs by the number of features in which they were implicated  
236 revealed that NQO1 and IL1RN were selected for eight of the fourteen traits, LMAN2, IGF2R,  
237 KHSRP, and CCL18 were selected for seven of the fourteen traits. Twenty-one total ENSPs were  
238 identified in at least five of the sixteen traits, seven of which were also quantified in the InCHIANTI  
239 1.3k panel (**Fig. 7a**). Linear models of the high impact panel that were trained on 80% of the BLSA  
240 cohort significantly predicted many clinical traits of the remaining 20% test set (**Fig. 7b**). Similarly,  
241 high impact panel linear models show held-out predictive potential when trained on 80% of the



242 InCHIANTI cohort and tested in the remaining 20% (**Fig. 7c**). Next, the high impact panel  
243 expression levels were condensed into a single continuous variable using principal component  
244 analysis. In this way, principal component 1 was used to represent each individual's senescence  
245 burden score. Ranking the BLSA and InCHIANTI cohorts by their composite senescence burden  
246 and plotting linear trends of the clinical traits walking pace, HDL, BMI, and CRP reveals that  
247 increasing senescence burden score shows the expected association with trait trending in the  
248 direction of poorer health (positively associated with BMI and CRP, negatively associated with  
249 walking pace and HDL), in both BLSA (**Fig. 7d**) and InCHIANTI (**Fig. S5b**). This suggests that  
250 the high impact panel could potentially be used as a proxy metric of individual senescence burden  
251 in a clinical setting.

252

### 253 **Validation of age and covariate independent clinical relevance of senescence signatures**

254 To evaluate the contribution of covariates such as age to the predictive potential of elastic net  
255 models, we compared covariate-only models to combined ENSP + covariate models. To select  
256 senescence signatures that are implicated in clinical traits irrespective of age and other  
257 covariates, such as race, sex, and estimated glomerular filtration rate (eGFR, a common marker  
258 of kidney function), these metrics were included in the elastic net modeling performed thus far  
259 and therefore contributed to the predictive potential of these models. To determine if the ENSPs  
260 show age and covariate independent predictive potential, analysis of variance (ANOVA) testing  
261 was used to compare covariate-only models to those that include ENSPs. ANOVA testing  
262 revealed that including ENSPs in linear models significantly improved the accuracy of covariate-  
263 only linear models (**Table S4**). Additionally, including ENSPs in covariate-only linear models  
264 substantially increased correlation coefficients (**Fig. S3a**), and ENSP-only models produced  
265 similar correlation coefficients to ENSP with covariates models (**Fig. S3a**). Due to association with  
266 body fat, a similar analysis was conducted using whole-body fat percent as an additional covariate  
267 along with age, sex, race, and eGFR to determine if ENSPs show body-fat independent predictive  
268 potential. ANOVA testing again revealed that ENSPs added significant additional predictive  
269 accuracy to models using only body fat and other covariates (**Table S4**), and adding ENSPs to  
270 body fat percent with other covariate-only linear models again increased the correlation coefficient  
271 for many clinical traits, particularly triglycerides, HDL, LDL, CRP, and fasting glucose (**Fig. S3b**).  
272 Additionally, for each clinical trait, the predictive potential of ENSPs was compared with a  
273 randomly selected group of proteins of the same group size. Permutation tests (100,000  
274 repetitions per trait) revealed that ENSPs often demonstrated better out-of-sample trait prediction  
275 potential than randomly selected proteins (**Fig S5a, Table S5**). These results implicate

276 senescence-associated proteins in BMI and other clinical traits independently of the effects of  
277 aging and other covariates.

278

## 279 **Discussion**

280

281 This study applied a novel nanoparticle-based MS strategy to identify SASPs from monocytes in  
282 fully supplemented culture conditions and revealed circulating senescence signatures that predict  
283 aging-associated clinical traits in humans. MS-based proteomics allows a comprehensive  
284 unbiased characterization of the cell secretome. Yet, the large numbers of proteins, such as  
285 albumin in FBS, in most culture media are a major hurdle in MS-based analysis of SASP proteins.  
286 Our group and others addressed this issue by using serum-free media<sup>30,32,41-44</sup>. However,  
287 prolonged absence of serum profoundly alters cellular phenotypes, metabolism, and viability. We  
288 initially observed dramatic loss of viability and induction of differentiation under serum starvation  
289 in THP-1 cells (data not shown), necessitating a new approach compatible with serum  
290 supplementation. Serum starvation can also trigger inhibition of mTORC1, initiate autophagy<sup>45</sup>  
291 and reduce protein synthesis, which greatly alter the global proteome of the cells and degrade  
292 the reliability of markers from the secretome. Moreover, mTOR is a potent regulator of the SASP  
293 in cultured cells<sup>46,47</sup>. Application of the automated, nanoparticle-based workflow here enabled the  
294 comprehensive profiling of the SASP in THP-1 monocytes under fully supplemented culture  
295 conditions and free of the confounders of starvation.

296 Our workflow adapted a recent technology that enables comprehensive proteomic  
297 analysis of the circulating proteome. This workflow leverages nanoparticles to aid in  
298 comprehensive detection of proteins in samples with a large dynamic range of protein  
299 concentrations<sup>31,35,36,48</sup>. In this approach, the protein mixture bound at the surface of nanoparticles  
300 in a protein sample, termed the 'protein corona', contains a reduced protein dynamic range and  
301 allows the detection and quantification of proteins that are normally undetectable in blood. The  
302 composition of the protein corona is reproducible and quantitative and, therefore, can be utilized  
303 for blood biomarker studies<sup>31,36,49,50</sup>. Because serum supplementation essentially produces the  
304 same dynamic range problem as conditioned medium, we reasoned that the same workflow would  
305 enable the comprehensive, quantitative, and unbiased profiling of the SASP under fully  
306 supplemented culture conditions. Indeed, we detected a dramatically increased number of human  
307 peptides in conditioned medium supplemented with FBS.

308 Despite the differences in the workflow and cell types between this study and our  
309 published SASP Atlas<sup>30</sup>, which focused on senescence signatures in fibroblasts, there were

310 notable similarities in the composition of the SASPs. Here, we detected at least a threefold  
311 increase in the SASP proteins versus SASP Atlas proteins. This is likely due to a combination of  
312 factors, likely including the different MS instrumentation and the fact that SASP factor secretion  
313 is greater in serum-supplemented conditions. Nonetheless, more than 40% of the published  
314 irradiation-induced fibroblast SASP factors were also detected in the inducer-matched monocyte  
315 SASP from the current study. Among the key pathway similarities were cellular detoxification and  
316 regulation of apoptotic processes and oxidative stress-induced pathways. Furthermore, the  
317 current study identified other well-known signatures of senescent cells. Prominent among these  
318 were highly elevated interferon-related proteins (**Fig. 3e**) and, most significantly, MX1, ISG15 and  
319 IFITM3 (FDR < 1e-25). Among all SASP factors, MX1 exhibited the largest and most significant  
320 protein increase (55-fold change, FDR = 2.23e-14). Notably, multiple interferon-response  
321 associated proteins significantly elevated in the monocyte SASP (FDR < 0.05) are among the  
322 proteins increased with age in plasma of BLSA participants (FDR < 0.05), including IFI16, OAS1,  
323 IFIH1, IFNGR1, IF9, IRF4, OASL and related pro-inflammatory cytokines. Moreover, OASL was  
324 selected among other top proteins in our high impact senescence panel (**Fig 7a**) based on its  
325 association with multiple clinical traits and ranked highest in the panel in importance, based on  
326 the average magnitude of its association with each trait. Collectively, these results further  
327 reinforce the robustness of the type-1 interferon response in senescent phenotypes and highlight  
328 their potential as senescence-associated biomarkers in circulation.

329 Our results are consistent with the premise that senescent cells, particularly senescent  
330 monocytes, may either contribute to or be driven by declines in diverse age-related and obesity-  
331 related clinical outcomes, including loss of mobility, increased body fat (BMI, fat percentage, waist  
332 size), increased blood pressure, elevated triglycerides and lipids, elevated glucose and A1C, and  
333 inflammation (CRP and IL6). These findings are also consistent with previous studies in multiple  
334 aging cohorts identifying senescence markers that are associated with diverse clinical traits of  
335 aging, such as frailty and cognitive decline. For example, SASP proteins, such as ICAM1, MMP7  
336 and Activin A, have been associated with a decline in physical activity in participants of the LIFE  
337 study<sup>28</sup>. In addition, plasma levels of 13 core SASP proteins, including CTSB, a component of the  
338 monocyte SASP, are associated with all-cause mortality and multimorbidity in the BLSA<sup>25</sup>. Few  
339 of the published SASP-derived protein associations were observed in the present study,  
340 highlighting the heterogeneity in senescent cell phenotypes based on cell-type. For example,  
341 GDF15 is notably missing from the monocyte SASP, while the most important SASP proteins  
342 (based on the number of associations, **Fig 7a**) identified in the present study are not among  
343 circulating senescence factors currently described<sup>22</sup>. These results are in line with the expected

344 heterogeneity of senescent cells based on cell type, and that diverse SASP emerging from  
345 different senescent cell populations might drive different phenotypes. These results further  
346 suggest the importance of developing type-specific (senotype-specific) senescence biomarker  
347 signatures for drawing connections between senotype and phenotype in future studies.

348 One of the striking findings of this study are the robust associations between the monocyte  
349 SASP and obesity-related outcomes, such as BMI and body fat, which were among the strongest  
350 associations observed. Of note, elastic net models based on monocyte SASP predicted out-of-  
351 sample waist size, triglycerides, fat mass in multiple compartments, BMI, fasting glucose, A1C,  
352 and blood pressure. An exploratory analysis of body-fat depots in the BLSA revealed that fat  
353 deposits in different locations, including thigh, arms, abdomen, and different types, including  
354 visceral, subcutaneous, and intramuscular, were all strongly predicted by a monocyte SASP  
355 elastic net model (Spearman correlation ranging from = 0.5074 to 0.7473, **Fig 5a**). However, body  
356 fat percentage, a measure of body fat corrected to overall body size, was most strongly predicted  
357 (cor=0.7913), suggesting that fat proportion, rather than overall mass, is likely associated with  
358 senescence. The associations of monocyte SASP and body fat and related outcomes is notably  
359 independent of age and other covariates (**Fig S3a, Table S4**). These results suggest a potential  
360 link between monocyte senescence and obesity. While the direction of causality cannot be  
361 definitively determined in the present study, there is ample evidence to support obesity as a driver  
362 of cellular senescence. Culture conditions that mimic aspects of obesity, such as high free-fatty  
363 acids or glucose, can drive cells into senescence in vitro<sup>51-53</sup>. Senescent cells accumulate in  
364 obesity and high-fat diet, particularly in adipose tissue<sup>54,55</sup>. Furthermore, the transplantation of  
365 senescent preadipocytes into mice fed high fat diet exacerbates declines in walking speed and  
366 endurance when compared with normal diet<sup>56</sup>. Obesity drives senescence in glial cells in mouse  
367 brains and their removal resulting in restored neurogenesis<sup>57</sup>. Thus, evidence strongly points to  
368 obesity as a disease-associated senescence inducer that can be decoupled from aging.  
369 Additionally, results from the CALERIE trial demonstrate the reduction of senescence biomarkers  
370 in individuals over 1-2 years of calorie restriction, further suggesting a link between senescence  
371 burden and diet, body composition and metabolism<sup>58</sup>. We speculate that at least some of the  
372 clinical traits described in this study can be attributed to obesity-associated senescent cells.  
373 Indeed, we observe that monocyte SASP-based elastic net models predict key obesity-associated  
374 clinical outcomes related to metabolism (fasting glucose, A1C), lipids (triglycerides, cholesterol),  
375 and blood pressure. Collectively these findings suggest the importance of considering obesity as  
376 a contributor to senescence and senescence-associated outcomes in humans. Importantly, these  
377 associations suggest that obese individuals may be among those that benefit most from

378 senotherapeutic interventions, and we propose that this population should be considered for  
379 inclusion in future trials of senolytics and senomorphics.

380         Given the known age-associations of senescent cells and many SASPs, one of the  
381 potential concerns of the present study, and all studies of senescence, are the potential  
382 contribution of covariates such as aging to the associations with age-related clinical outcomes,  
383 and whether they can be separated from age-related processes. In this study, we were indeed  
384 able to show that predictive models based on SASP added value to models that include covariates  
385 (age, sex, race, and eGFR) and were clinically meaningful in predicting outcomes such as obesity.  
386 Further, to mitigate the risk of overfitting our models, which are based on large numbers of  
387 features, elastic net modeling was leveraged in this study. To further test the strength of the  
388 model, we were able to show that our elastic net model selected on monocyte SASP far  
389 outperformed linear models based using the same number of randomly selected proteins across  
390 the 7k SomaScan assay (**Fig S5a**). To ensure the robustness of the findings, we report  
391 associations are based on prediction out-of-sample clinical outcomes (independent of the training  
392 set), including a subset of the clinical associations that replicated across BLSA and InCHIANTI  
393 (**Fig 6a**).

394         One of the clinically meaningful findings of his study was that, despite the large number of  
395 total SASP proteins identified, a relatively small panel of these also robustly predicted a set of  
396 age- and obesity-associated clinical outcomes, including inflammation (IL6, CRP), lipids (HDL,  
397 LDL), glucose (A1c, fasting glucose), blood pressure, walking speed and pace, and BMI. Notably,  
398 even though a fraction of this panel was measured in both BLSA and InCHIANTI for replication,  
399 multiple predictions were replicated across aging studies, supporting the robustness of using  
400 selected high impact proteins, for clinical associations. A defined panel of proteins may be  
401 clinically advantageous in that the full panel, or selected proteins, can be more readily tested and  
402 applied in multiple studies without building new models or making costly measurements of large  
403 numbers of proteins. In future studies, it will be of interest to further validate this panel in diverse  
404 human cohorts and test their utility to predict a range of aging- and obesity-related outcomes.  
405 Several proteins in the panel are consistent with senescence biology and have known  
406 associations with outcomes with elevated senescent cell burden. Notably, the cytokine CCL18  
407 (also known as PARC) previously showed the strongest association with mortality among 28  
408 SASPs in a study of 1923 individuals over the age of 65<sup>59</sup>, and has been associated with disease-  
409 progression or negative outcomes in a range of diseases including cancer <sup>60</sup>, atherosclerosis <sup>61</sup>,  
410 and lung disease <sup>62</sup>. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a senescence-  
411 associated protein that, when targeted with a senolytic vaccine, results in the reduction of

412 senescence burden and improvements in aging and obesity-related outcomes in mice, including  
413 improved glucose homeostasis on high fat diet, and reduced aortic plaque size in APOE KO  
414 mice<sup>63</sup>. LGALS3BP is a previously reported core SASP<sup>30</sup>, is associated with diverse  
415 malignancies<sup>64</sup> and sepsis<sup>65</sup>. In future studies, it will be valuable to validate the associations of  
416 the set of proteins in the high impact senescence panel with elevated senescence burden and  
417 evaluate their potential roles as either drivers or biomarkers of disease outcomes.

418 This study has several limitations. SASP factors in plasma can be contributed by a variety  
419 of cells and tissues in the body. Thus, it is not possible to track the originating tissues of SASPs  
420 in circulation or to verify whether circulating proteins were released by senescent cells or other  
421 secreting cells with common secretory factors, such as activated immune cells. Senescence  
422 signatures are numerous and heterogeneous by cell type<sup>3</sup>, and examining clinical associations of  
423 senescence signatures from a variety of tissue types is warranted. Studying the SASP from  
424 specific cell types can help dissect the role of individual cells in the progression of age-associated  
425 clinical traits. In future studies, it may be of interest to identify tissue-specific (senotype-specific)  
426 senescent signatures and examine their clinical associations in human cohorts. These studies  
427 may shed light on the contributing tissue and senotype-specific senescent cell populations on  
428 aging- and obesity-related outcomes and identify more sensitive and specific biomarkers. One  
429 limitation of the cross-study validation performed is the difference in the proteomic panels applied  
430 in each study, where the BLSA was performed on the newer generation of the SomaScan panel  
431 versus the InCHIANTI study. While this affected the strength of the predictions, multiple outcomes  
432 remained significant with smaller panels, highlighting some of the more robust associations. It will  
433 be valuable going forward to test the cross-study validations both in studies that utilize the  
434 complete proteomic assay, and in studies that utilize different proteomic platforms such as UK  
435 Biobank, to better understand the predictors that are most robust to differences in proteomic  
436 methods. Finally, longitudinal proteomic measurements will be useful in future studies for  
437 evaluating whether SASP protein trajectories can be more sensitive in predicting clinical  
438 outcomes.

439 In summary, we showed that SASP factors from monocytes have a high association with  
440 aging-associated clinical traits and can serve as biomarkers to predict biological aging. Using  
441 nanoparticle-based enrichment coupled with MS enabled comprehensive characterization of the  
442 secretome from senescent monocytes in culture in serum-supplemented culture conditions. Our  
443 results highlight a novel approach to study the cellular secretome under physiological conditions.  
444 Moreover, this study sheds light on clinical associations of circulating monocyte SASPs in human

445 longitudinal studies and identifies possible biomarkers of senescence that could potentially inform  
446 future senotherapeutic trials in obese and aged individuals.

447

## 448 **Methods**

### 449 **Cell culture and senescence induction**

450 THP-1 human monocytes (ATCC, Manassas, VA; #TIB-202) were cultured in RPMI 1640 medium  
451 (Thermo Fisher Scientific Inc., Waltham, MA; #11875119) supplemented with 10% FBS (Thermo  
452 Fisher Scientific; #26140079) and 1% pen strep (Thermo Fisher Scientific; # 15070063) in a 20%  
453 O<sub>2</sub>, 5% CO<sub>2</sub> incubator. To determine the optimum conditions for induction of senescence in  
454 monocytes, proliferating THP-1 cells were exposed to different doses of ionizing ( $\gamma$ ) radiation (IR;  
455 5, 7.5, and 10 Gy) using the Gammacell 40 Exactor, a Cesium-137 based irradiator (Nordion Inc.,  
456 Canada); thereafter, cell viability and senescence markers were assessed over different  
457 timepoints. Cell viability was measured using the CellTiter-Glo® Luminescent Cell Viability Assay  
458 (Promega Corporation, Madison, WI; #G7570) as per the manufacturer's instructions. IR radiation  
459 of 7.5 Gy and culture up to 7 days were optimum for senescence induction and were used for all  
460 further experiments. Proliferating cells were used as non-senescent controls for all experiments.

461

### 462 **EdU incorporation assay**

463 Cell proliferation was assessed using the Click-iT™ Plus EdU Cell Proliferation Kit (Thermo Fisher  
464 Scientific; #C10640), following the manufacturer's instructions. Briefly, 20,000 cells per well were  
465 seeded in 100  $\mu$ L of medium in 96-well plates. At 6 days after irradiation, cells were incubated  
466 with 20  $\mu$ M 5-ethynyl-2'-deoxyuridine (EdU) overnight at 37°C. Next day, cells were fixed using  
467 3.7% formaldehyde for 15 min, followed by permeabilization with 0.5% Triton X-100 for 20 min.  
468 Cells were then incubated with Alexa Fluor picolyl azide and Hoechst 33342 dye for 30 min each.  
469 The resulting images were captured by a fluorescence microscope (BZ-X Analyzer, Keyence  
470 Corporation, Itasca, IL). The percentage of cells that showed EdU incorporation corresponded to  
471 the percentage proliferating cells.

472

### 473 **Quantitative PCR (qPCR) analysis**

474 Total RNA was isolated using a Direct-zol RNA Miniprep Kit (Zymo Research, Irvine, CA;  
475 #R2052), and 500 ng of total RNA was reverse transcribed using Maxima reverse transcriptase  
476 (Thermo Fisher Scientific; # EP0741) and random hexamers. For reverse transcription followed  
477 by quantitative RT-qPCR analysis, 0.1  $\mu$ l cDNA was employed with 250 nM of gene-specific

478 primers (**Table S6**) and KAPA SYBR® FAST qPCR Kits (KAPA Biosystems Inc., Wilmington, MA;  
479 #) on the QuantStudio 3 Realtime PCR system (Thermo Fisher Scientific). Relative RNA levels  
480 were calculated after normalizing to *ACTB* mRNA encoding the housekeeping protein  $\beta$ -actin  
481 using the  $2^{-\Delta\Delta Ct}$  method. QPCR experiments were performed with seven biological replicates of  
482 IR-treated and proliferating controls. Statistical analysis was performed using GraphPad Prism  
483 v10. Results are presented as the mean  $\pm$  SD. Comparisons between the two groups were made  
484 using students *t*-test. Statistical significance was considered at  $p < 0.05$ .

485

#### 486 **Senescence-associated $\beta$ -galactosidase (SA- $\beta$ -gal) assay**

487 Senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -gal) activity was assessed using the Cellular  
488 Senescence Plate Assay Kit - SPiDER- $\beta$ Gal (Dojindo Molecular Technologies Inc., Rockville, MD;  
489 #SG05), following the manufacturer's instructions. Briefly, 150,000 cells were seeded in 2 mL of  
490 medium in 6-well plates. On the 7<sup>th</sup> day after IR, cells were lysed and incubated with SPiDER  $\beta$ -  
491 gal for 1 h at 37°C, and SPiDER  $\beta$ -gal fluorescence intensity was measured at 535 nm excitation  
492 and 580 nm emission using a microplate reader.

493

#### 494 **Sample preparation for mass spectrometry**

495 SASPs from senescent and proliferating THP-1 monocytes were collected, based on a modified  
496 version of the protocol from Neri et al.<sup>32</sup>, adjusting the protocol so that complete medium  
497 (supplemented with 10% FBS) was used in place of serum-free medium because of the  
498 downstream processing of samples with the Proteograph workflow. Briefly, THP-1 cells were  
499 grown in T75 flasks to sub-confluence prior to induction of senescence. For senescent samples,  
500 cells were shifted to fresh complete medium 7 days after irradiation, and conditioned medium  
501 containing SASP was collected after 48 h. Conditioned media from proliferating cells were  
502 similarly collected after 48-h incubation in fresh complete medium. Conditioned medium was then  
503 centrifuged at 10,000 x g for 15 min to pellet down cell debris and concentrated using 3 kDa  
504 molecular mass cut-off filters. One milliliter of each conditioned medium sample was then  
505 aliquoted into tubes for downstream preparation, for a total of 14 samples (seven senescent and  
506 seven non-senescent).

507 The conditioned medium samples were processed as described<sup>34</sup> on the SP100  
508 Automation Instrument coupled with Proteograph XT Assay Kits (Seer, Inc). Briefly, samples were  
509 incubated with two chemically distinct nanoparticle suspensions supplied in the assay kits.  
510 Nanoparticle-bound proteins were captured by incubation and a series of gentle washes. The  
511 resulting protein coronas were reduced, alkylated, and digested with Trypsin/Lys-C to generate



512 peptides for MS analysis. The peptide mixture was desalted using solid phase-extraction. All steps  
513 in the preparation of peptides were conducted automatically by the SP100, which produces two  
514 peptide fractions per sample, one fraction for each nanoparticle suspension.

515 In addition to the preparation of 14 nanoparticle-processed samples, six matched neat  
516 samples were prepared (three senescent and three non-senescent). Neat samples were  
517 processed in parallel with the other samples, except no nanoparticles were added and no protein  
518 corona was captured. Essentially, neat samples are equivalent to a standard digestion protocol  
519 and are used for comparison against standard methods. After processing of samples with the  
520 Proteograph XT workflow, 34 peptide samples were generated for downstream MS analysis: 28  
521 experimental samples (14 replicates with two nanoparticle fractions each) and six matched neat  
522 samples.

523

### 524 **Liquid chromatography–mass spectrometry**

525 All samples were analyzed using a Vanquish Neo UHPLC system coupled to an Orbitrap Astral  
526 mass spectrometer (Thermo Fisher Scientific) with a NanoSpray Flex source (Thermo Fisher  
527 Scientific). Peptides (400 ng of each sample) were loaded on Acclaim PepMap 100 C18 (0.3 mm  
528 ID x 5 mm) trap column and then separated on a 50-cm  $\mu$ PAC analytical column (PharmaFluidics,  
529 Belgium) at a flow rate of 1.0  $\mu$ L/min using a gradient of 4–35% solvent B (0.1% formic acid in  
530 acetonitrile) mixed into solvent A (0.1% formic acid in water) over 20.8 min and a total run time of  
531 24 min. The MS data were acquired in data-independent acquisition (DIA) mode with a normalized  
532 HCD-collision energy of 25% and a default charge state of +2. MS1 spectra were acquired in the  
533 Orbitrap every 0.6 s at a resolving power of 240,000 at  $m/z$  200 over  $m/z$  380–980. The MS<sup>1</sup>  
534 normalized AGC target was 500% ( $5 \times 10^6$  charges) with a MaxIT of 5 ms. For MS/MS experiments,  
535 the DIA experiment was set to have a 3  $m/z$  isolation window making 199 DIA scan events across  
536 the precursor isolation windows spanned 380–980. MS2 scans were collected from 150-2000  
537  $m/z$ . DIA MS<sup>2</sup> scans were acquired in Astral analyzer with a normalized AGC target of 500%  
538 ( $5 \times 10^4$  charges) to better control the ion population using MaxIT that was set to 5 ms. Window  
539 placement optimization was turned on. A source voltage of 1500 V and an ion transfer tube  
540 temperature of 280 °C were used for all experiments.

541

### 542 **Protein identification and quantitative analysis pipeline**

543 Data were analyzed using the Proteograph™ Analysis Suite (PAS) and the DIA-NN v1.8.1  
544 algorithm to perform the peptide identification and quantification using an *in silico*-predicted  
545 library, based on a combined database containing both Uniprot human and bovine proteomes

546 (4/2022 builds, 105,533 entries including isoform and TrEMBL). Match between runs was  
547 enabled. Otherwise, all DIA-NN settings were set to default. FDR was set to 1% for filtering  
548 identifications at the peptide and protein group levels. Peptide quantification was performed using  
549 a max representation approach, where the single quantification value for a particular peptide  
550 represents the quantitation value of the nanoparticle most frequently measured across all  
551 samples, and standard peptide-to-protein rollup was used on selected peptide values.  
552 Furthermore, to specifically identify the monocyte SASP and eliminate proteins originating from  
553 the FBS and unambiguously remove non-human peptides, all the peptides that mapped to the  
554 bovine proteome, or both human and bovine proteins, were removed from further analysis. Scaled  
555 intensities of human-unique peptides were aggregated to generate protein intensities using the  
556 MaxLFQ algorithm, implemented in the R/Bioconductor package iq (version 1.9.12)<sup>66</sup>. Differential  
557 analysis was conducted on the protein intensities between PRO and SEN samples using the  
558 R/Bioconductor package limma (version 3.58.1)<sup>67</sup>. Multiple testing was corrected using the  
559 Benjamini-Hochberg procedure.

560

### 561 **Pathway analysis**

562 Gene Ontology analysis was performed using ClusterProfiler version 4.6.0<sup>68,69</sup> in Rstudio to  
563 identify the biological processes and molecular functions enriched among the differentially  
564 expressed proteins. A background list of all proteins was utilized in each analysis. In Fig. 3e, the  
565 background list of proteins included all human proteins identified by MS. In Fig. 3g, the  
566 background list consisted of all proteins identified in both the fibroblast and monocyte secretomes.  
567 In Fig. 4c, the background list of proteins included all proteins that overlapped between the  
568 SomaScan 7K assay and the monocyte secretome proteins. All pathways depicted in main figures  
569 were statistically significant after background correction and multiple-testing correction, with  
570 adjusted  $p < 0.05$ , calculated by the Benjamini-Hochberg Procedure. Analysis was conducted  
571 using R version 4.2.0 (R Development Core Team, Vienna, Austria) and RStudio 2023.06.0-421  
572 (RStudio, Boston, MA).

573

### 574 **Clinical data**

575 We used clinical data from the BLSA and InCHIANTI cohorts to determine the association of  
576 senescence markers with physiological markers of health and aging. The BLSA study is a  
577 population-based study that started in 1958 to evaluate the contributors of healthy aging in  
578 subjects recruited from the DC/Baltimore metropolitan area that are 20 years old and older<sup>70-72</sup>.  
579 It involves a data collection of clinical parameters, such as waist circumference, BMI and blood

580 pressure that are assessed during a standard medical exam. Blood tests were performed at a  
581 Clinical Laboratory Improvement Amendments certified clinical laboratory at Medstar Harbor  
582 Hospital, Baltimore, MD. Total cholesterol was measured using alkaline phosphatase, HDL and  
583 LDL with dextran magnetic beads, triglycerides with colorimetric methods, glucose with glucose  
584 oxidase using the Vitros system (Ortho Clinical Diagnostics, Raritan, NJ). Serum inflammatory  
585 markers IL6 (R&D System, Minneapolis, MN) and CRP (Alpco, Salem, NH) were measured with  
586 enzyme-linked immunosorbent assay (ELISA). HbA1C levels were measured using liquid  
587 chromatography by an automated DiaSTAT analyzer (Bio-Rad, Oakland, CA). Grip strength was  
588 measured three times on each of the right and left hand and the highest average grip strength  
589 was reported. Usual gait speed was measured in two trials of a 6-m walk and the faster time  
590 between the two trials is used for analysis. Body fat measurements were made using CT/dual x-  
591 ray absorptiometry scans. The BLSA protocol (03AG0325) was approved by the institutional  
592 review board of the National Institute of Environmental Health Science, part of the National  
593 Institutes of Health. To avoid possible confounding effects of medication use, patients taking  
594 diabetes or hypertension medication had their A1C or blood pressure values excluded from  
595 statistical analysis.

596 The InCHIANTI is a similar population-based study of aging conducted in the Chianti  
597 region of Tuscany, Italy previously described in more detail <sup>73</sup>. Residents from the population  
598 registry of Greve in Chianti (a rural area) and Bagno a Ripoli (near Florence) ranging in age from  
599 21 to 102 years participated in the study. The study (exemption #11976) protocol was approved  
600 by Medstar Research Institute (Baltimore, Maryland), the Italian National Institute of Research  
601 and Care of Aging Institutional Review, and the Internal Review Board of the National Institute for  
602 Environmental Health Sciences (NIEHS). All participants provided written informed consent.

603

#### 604 **SOMAscan assay**

605 The BLSA plasma proteomic study involved profiling for 7,596 SOMAmers using the 7K  
606 SOMAscan Assay, whereas the InCHIANTI involved profiling for 1322 SOMAmers using the 1.3K  
607 SOMAscan Assay at the Trans-NIH Center for Human Immunology and Autoimmunity, and  
608 Inflammation (CHI), National Institute of Allergy and Infectious Disease, National Institutes of  
609 Health (Bethesda, MD). Proteomic assessment and data normalization for each of the assays  
610 were conducted as reported<sup>37,74</sup>. Plasma protein concentrations were directly proportional to the  
611 abundance of the SOMAmer reagents that were reported in relative fluorescence units. The  
612 reliability and variability of the SomaScan assay measurements has been previously rigorously  
613 evaluated and applied in the BLSA <sup>37,75</sup>.

## 614 **Elastic-net modeling**

615 To avoid overfitting of simple linear models, Elastic-net modeling, a penalized linear regression  
616 machine learning technique, was used for feature selection of the most biologically relevant  
617 proteins. Elastic-net modeling was used due to its ability to perform unbiased feature selection,  
618 and because it can cope with high collinearity of features. Elastic Net contains two tuning  
619 parameters, alpha and lambda, that determine the nature of feature selection used. The value for  
620 alpha can range from 0 (Ridge regression with no feature elimination) to 1 (Lasso regression  
621 which selects the smallest number of features). An alpha of 1 was used to apply the strictest level  
622 of feature selection and reveal the smallest number of highly relevant features. The lambda  
623 parameter determines the strength of the penalty, with a higher penalty eliminating more features.  
624 The package glmnet<sup>76</sup> (version 4.1-6) randomly selected subsets of the dataset for cross-  
625 validation to find the lambda value with the smallest mean squared error. Due to its feature tuning  
626 method, this package produces slightly variable results. To account for this and to reduce  
627 variability, the package was run 100 times for each trait, and the most accurate penalty term was  
628 found across all runs.

629

## 630 **Data Availability**

631 All raw mass spectrometry data files and associated quantitative and statistical reports, metadata,  
632 and supplemental data are available on MassIVE (dataset identifier: MSV000095315). FTP  
633 download link: <ftp://massive.ucsd.edu/v08/MSV000095315/>.

634

## 635 **Code Availability**

636 R scripts for the core elastic net analysis described are available at  
637 [https://github.com/geroproteomics/EN\\_Repeat/blob/main/EN\\_Repeat](https://github.com/geroproteomics/EN_Repeat/blob/main/EN_Repeat).

638

## 639 **Acknowledgements**

640 This work was supported by the National Institute on Aging (NIA) Intramural Research Program  
641 (IRP), NIH. N.B. was supported by a SenNet NIH Common Fund Grant (NIA U54 AG079779, PI:  
642 Elisseeff) and a Hevolution GRO grant (HF-GRO-23-1199068-44). We gratefully acknowledge  
643 Lauren Brick and NIDA/NIA Visual Media for assistance in figure preparation and Gary Howard  
644 for editing of the manuscript.

645

646

## 647 References

- 648 1 López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of  
649 aging: An expanding universe. *Cell* **186**, 243-278,  
650 doi:<https://doi.org/10.1016/j.cell.2022.11.001> (2023).
- 651 2 Hayflick, L. The limited in vitro lifetime of human diploid cell strains. *Experimental Cell*  
652 *Research* **37**, 614-636, doi:[https://doi.org/10.1016/0014-4827\(65\)90211-9](https://doi.org/10.1016/0014-4827(65)90211-9) (1965).
- 653 3 Tchkonina, T., Zhu, Y., Deursen, J. v., Campisi, J. & Kirkland, J. L. Cellular senescence  
654 and the senescent secretory phenotype: therapeutic opportunities. *The Journal of*  
655 *Clinical Investigation* **123**, 966-972, doi:10.1172/JCI64098 (2013).
- 656 4 Zhang, X. *et al.* Rejuvenation of the aged brain immune cell landscape in mice through  
657 p16-positive senescent cell clearance. *Nat Commun* **13**, 5671, doi:10.1038/s41467-022-  
658 33226-8 (2022).
- 659 5 Baker, D. J. & Petersen, R. C. Cellular senescence in brain aging and  
660 neurodegenerative diseases: evidence and perspectives. *J Clin Invest* **128**, 1208-1216,  
661 doi:10.1172/JCI95145 (2018).
- 662 6 Bussian, T. J. *et al.* Clearance of senescent glial cells prevents tau-dependent pathology  
663 and cognitive decline. *Nature* **562**, 578-582, doi:10.1038/s41586-018-0543-y (2018).
- 664 7 Ogrodnik, M. *et al.* Whole-body senescent cell clearance alleviates age-related brain  
665 inflammation and cognitive impairment in mice. *Aging Cell* **20**, e13296,  
666 doi:10.1111/accel.13296 (2021).
- 667 8 Childs, B. G. *et al.* Senescent intimal foam cells are deleterious at all stages of  
668 atherosclerosis. *Science* **354**, 472-477, doi:10.1126/science.aaf6659 (2016).
- 669 9 Walker, K. A., Basisty, N., Wilson, D. M., 3rd & Ferrucci, L. Connecting aging biology  
670 and inflammation in the omics era. *J Clin Invest* **132**, doi:10.1172/JCI158448 (2022).
- 671 10 Camell, C. D. *et al.* Senolytics reduce coronavirus-related mortality in old mice. *Science*  
672 **373**, doi:10.1126/science.abe4832 (2021).
- 673 11 Yousefzadeh, M. J. *et al.* An aged immune system drives senescence and ageing of  
674 solid organs. *Nature* **594**, 100-105, doi:10.1038/s41586-021-03547-7 (2021).
- 675 12 Franceschi, C. & Campisi, J. Chronic Inflammation (Inflammaging) and Its Potential  
676 Contribution to Age-Associated Diseases. *The Journals of Gerontology: Series A* **69**, S4-  
677 S9, doi:10.1093/gerona/glu057 (2014).
- 678 13 Baker, D. J. *et al.* Naturally occurring p16Ink4a-positive cells shorten healthy lifespan.  
679 *Nature* **530**, 184-189, doi:10.1038/nature16932 (2016).
- 680 14 Chaib, S., Tchkonina, T. & Kirkland, J. L. Cellular senescence and senolytics: the path to  
681 the clinic. *Nat Med* **28**, 1556-1568, doi:10.1038/s41591-022-01923-y (2022).
- 682 15 Baker, D. J. *et al.* Clearance of p16Ink4a-positive senescent cells delays ageing-  
683 associated disorders. *Nature* **479**, 232-236, doi:10.1038/nature10600 (2011).
- 684 16 Childs, B. G. *et al.* Senescent cells: an emerging target for diseases of ageing. *Nature*  
685 *Reviews Drug Discovery* **16**, 718-735, doi:10.1038/nrd.2017.116 (2017).
- 686 17 Lee, K. A., Flores, R. R., Jang, I. H., Saathoff, A. & Robbins, P. D. Immune Senescence,  
687 Immunosenescence and Aging. *Frontiers in Aging* **3**, 2673-6217 (2022).
- 688 18 Yousefzadeh, M. J. *et al.* An aged immune system drives senescence and ageing of  
689 solid organs. *Nature* **594**, 100-105, doi:10.1038/s41586-021-03547-7 (2021).
- 690 19 Ong, S.-M. *et al.* The pro-inflammatory phenotype of the human non-classical monocyte  
691 subset is attributed to senescence. *Cell Death & Disease* **9**, 266, doi:10.1038/s41419-  
692 018-0327-1 (2018).
- 693 20 Lin, Y. *et al.* Circulating monocytes expressing senescence-associated features are  
694 enriched in COVID-19 patients with severe disease. *Aging Cell* **22**, 1474-9726,  
695 doi:10.1111/accel.14011 (2023).

- 696 21 Dey, A. K. *et al.* Translating Senotherapeutic Interventions into the Clinic with Emerging  
697 Proteomic Technologies. *Biology (Basel)* **12**, doi:10.3390/biology12101301 (2023).
- 698 22 Suryadevara, V. *et al.* SenNet recommendations for detecting senescent cells in  
699 different tissues. *Nat Rev Mol Cell Biol*, doi:10.1038/s41580-024-00738-8 (2024).
- 700 23 Basisty, N., Kale, A., Patel, S., Campisi, J. & Schilling, B. The power of proteomics to  
701 monitor senescence-associated secretory phenotypes and beyond: toward clinical  
702 applications. *Expert Rev Proteomics* **17**, 297-308, doi:10.1080/14789450.2020.1766976  
703 (2020).
- 704 24 Tanaka, T. *et al.* Plasma proteomic signature of age in healthy humans. *Aging Cell* **17**,  
705 e12799, doi:10.1111/accel.12799 (2018).
- 706 25 Tanaka, T. *et al.* Plasma proteomic biomarker signature of age predicts health and life  
707 span. *eLife* **9**, e61073, doi:10.7554/eLife.61073 (2020).
- 708 26 Ubaida-Mohien, C. *et al.* Discovery proteomics in aging human skeletal muscle finds  
709 change in spliceosome, immunity, proteostasis and mitochondria. *Elife* **8**,  
710 doi:10.7554/eLife.49874 (2019).
- 711 27 Tsitsipatis, D. *et al.* Proteomes of primary skin fibroblasts from healthy individuals reveal  
712 altered cell responses across the life span. *Aging Cell* **21**, e13609,  
713 doi:10.1111/accel.13609 (2022).
- 714 28 Fielding, R. A. *et al.* Associations between biomarkers of cellular senescence and  
715 physical function in humans: observations from the lifestyle interventions for elders  
716 (LIFE) study. *GeroScience* **44**, 2757-2770, doi:10.1007/s11357-022-00685-2 (2022).
- 717 29 Shin, J.-W., Lee, E., Han, S., Choe, S.-A. & Jeon, O. H. Plasma Proteomic Signature of  
718 Cellular Senescence and Markers of Biological Aging Among Postmenopausal Women.  
719 *Rejuvenation Research* **25**, 141-148, doi:10.1089/rej.2022.0024 (2022).
- 720 30 Basisty, N. *et al.* A proteomic atlas of senescence-associated secretomes for aging  
721 biomarker development. *PLOS Biology* **18**, e3000599, doi:10.1371/journal.pbio.3000599  
722 (2020).
- 723 31 Blume, J. A.-O. X. *et al.* Rapid, deep and precise profiling of the plasma proteome with  
724 multi-nanoparticle protein corona. *Nature Communications* **11**, 3662 (2020).
- 725 32 Neri, F., Basisty, N., Desprez, P.-Y., Campisi, J. & Schilling, B. Quantitative Proteomic  
726 Analysis of the Senescence-Associated Secretory Phenotype by Data-Independent  
727 Acquisition. *Curr Protoc* **1**, e32, doi:10.1002/cpz1.32 (2021).
- 728 33 Knecht, S. *et al.* An Introduction to Analytical Challenges, Approaches, and Applications  
729 in Mass Spectrometry-Based Secretomics. *Mol Cell Proteomics* **22**, 100636,  
730 doi:10.1016/j.mcpro.2023.100636 (2023).
- 731 34 Blume, J. E. *et al.* Rapid, deep and precise profiling of the plasma proteome with multi-  
732 nanoparticle protein corona. *Nat Commun* **11**, 3662, doi:10.1038/s41467-020-17033-7  
733 (2020).
- 734 35 Ferdosi, S. *et al.* Engineered nanoparticles enable deep proteomics studies at scale by  
735 leveraging tunable nano-bio interactions. *Proc Natl Acad Sci U S A* **119**, e2106053119,  
736 doi:10.1073/pnas.2106053119 (2022).
- 737 36 Donovan, M. K. R. *et al.* Functionally distinct BMP1 isoforms show an opposite pattern of  
738 abundance in plasma from non-small cell lung cancer subjects and controls. *PLoS One*  
739 **18**, e0282821, doi:10.1371/journal.pone.0282821 (2023).
- 740 37 Candia, J., Daya, G. N., Tanaka, T., Ferrucci, L. & Walker, K. A. Assessment of  
741 variability in the plasma 7k SomaScan proteomics assay. *Sci Rep* **12**, 17147,  
742 doi:10.1038/s41598-022-22116-0 (2022).
- 743 38 Cordon, J. *et al.* Identification of Clinically Relevant Brain Endothelial Cell Biomarkers in  
744 Plasma. *Stroke* **54**, 2853-2863, doi:10.1161/STROKEAHA.123.043908 (2023).

- 745 39 Evans, D. S. *et al.* Proteomic Analysis of the Senescence-Associated Secretory  
746 Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging  
747 Traits. *J Gerontol A Biol Sci Med Sci* **79**, doi:10.1093/gerona/glad265 (2024).
- 748 40 Tanaka, T. *et al.* Plasma proteomic biomarker signature of age predicts health and life  
749 span. *Elife* **9**, doi:10.7554/eLife.61073 (2020).
- 750 41 Stastna, M. & Van Eyk, J. E. Investigating the secretome: lessons about the cells that  
751 comprise the heart. *Circ Cardiovasc Genet* **5**, o8-o18,  
752 doi:10.1161/CIRCGENETICS.111.960187 (2012).
- 753 42 Samsonraj, R. M., Law, S. F., Chandra, A. & Pignolo, R. J. An unbiased proteomics  
754 approach to identify the senescence-associated secretory phenotype of human bone  
755 marrow-derived mesenchymal stem cells. *Bone Rep* **18**, 101674,  
756 doi:10.1016/j.bonr.2023.101674 (2023).
- 757 43 Ozcan, S. *et al.* Unbiased analysis of senescence associated secretory phenotype  
758 (SASP) to identify common components following different genotoxic stresses. *Aging*  
759 (*Albany NY*) **8**, 1316-1329, doi:10.18632/aging.100971 (2016).
- 760 44 Wiley, C. D. *et al.* SILAC Analysis Reveals Increased Secretion of Hemostasis-Related  
761 Factors by Senescent Cells. *Cell Rep* **28**, 3329-3337 e3325,  
762 doi:10.1016/j.celrep.2019.08.049 (2019).
- 763 45 Mejlvang, J. *et al.* Starvation induces rapid degradation of selective autophagy receptors  
764 by endosomal microautophagy. *Journal of Cell Biology* **217**, 3640-3655 (2019).
- 765 46 Herranz, N. *et al.* mTOR regulates MAPKAPK2 translation to control the senescence-  
766 associated secretory phenotype. *Nat Cell Biol* **17**, 1205-1217, doi:10.1038/ncb3225  
767 (2015).
- 768 47 Laberge, R. M. *et al.* mTOR regulates the pro-tumorigenic senescence-associated  
769 secretory phenotype by promoting IL1A translation. *Nat Cell Biol* **17**, 1049-1061,  
770 doi:10.1038/ncb3195 (2015).
- 771 48 Suhre, K. *et al.* Nanoparticle enrichment mass-spectrometry proteomics identifies  
772 protein-altering variants for precise pQTL mapping. *Nat Commun* **15**, 989,  
773 doi:10.1038/s41467-024-45233-y (2024).
- 774 49 Ferdosi, S. *et al.* Engineered nanoparticles enable deep proteomics studies at scale by  
775 leveraging tunable nano–bio interactions. *Proceedings of the National Academy of*  
776 *Sciences* **119**, e2106053119, doi:doi:10.1073/pnas.2106053119 (2022).
- 777 50 Huang, T. *et al.* Protein Coronas on Functionalized Nanoparticles Enable Quantitative  
778 and Precise Large-Scale Deep Plasma Proteomics. *bioRxiv*,  
779 doi:10.1101/2023.08.28.555225 (2023).
- 780 51 Ishaq, A., Tchkonja, T., Kirkland, J. L., Siervo, M. & Saretzki, G. Palmitate induces DNA  
781 damage and senescence in human adipocytes in vitro that can be alleviated by oleic  
782 acid but not inorganic nitrate. *Exp Gerontol* **163**, 111798,  
783 doi:10.1016/j.exger.2022.111798 (2022).
- 784 52 Xue, W. J. *et al.* High glucose and palmitic acid induces neuronal senescence by  
785 NRSF/REST elevation and the subsequent mTOR-related autophagy suppression. *Mol*  
786 *Brain* **15**, 61, doi:10.1186/s13041-022-00947-2 (2022).
- 787 53 Maeda, M., Hayashi, T., Mizuno, N., Hattori, Y. & Kuzuya, M. Intermittent high glucose  
788 implements stress-induced senescence in human vascular endothelial cells: role of  
789 superoxide production by NADPH oxidase. *PLoS One* **10**, e0123169,  
790 doi:10.1371/journal.pone.0123169 (2015).
- 791 54 Minamino, T. *et al.* A crucial role for adipose tissue p53 in the regulation of insulin  
792 resistance. *Nature Medicine* **15**, 1082-1087, doi:10.1038/nm.2014 (2009).
- 793 55 Schafer, M. J. *et al.* Exercise Prevents Diet-Induced Cellular Senescence in Adipose  
794 Tissue. *Diabetes* **65**, 1606-1615, doi:10.2337/db15-0291 (2016).

- 795 56 Xu, M. *et al.* Senolytics improve physical function and increase lifespan in old age. *Nat*  
796 *Med* **24**, 1246-1256, doi:10.1038/s41591-018-0092-9 (2018).
- 797 57 Ogrodnik, M. *et al.* Obesity-Induced Cellular Senescence Drives Anxiety and Impairs  
798 Neurogenesis. *Cell Metabolism* **29**, 1061-1077 (2019).
- 799 58 Aversa, Z. *et al.* Calorie restriction reduces biomarkers of cellular senescence in  
800 humans. *Aging Cell* **23**, e14038, doi:10.1111/accel.14038 (2024).
- 801 59 St Sauver, J. L. *et al.* Biomarkers of cellular senescence and risk of death in humans.  
802 *Aging Cell* **22**, e14006, doi:10.1111/accel.14006 (2023).
- 803 60 Korbecki, J., Olbromski, M. & Dziegiel, P. CCL18 in the Progression of Cancer. *Int J Mol*  
804 *Sci* **21**, doi:10.3390/ijms21217955 (2020).
- 805 61 Singh, A. *et al.* CCL18 aggravates atherosclerosis by inducing CCR6-dependent T-cell  
806 influx and polarization. *Front Immunol* **15**, 1327051, doi:10.3389/fimmu.2024.1327051  
807 (2024).
- 808 62 Sin, D. D. *et al.* Serum PARC/CCL-18 concentrations and health outcomes in chronic  
809 obstructive pulmonary disease. *Am J Respir Crit Care Med* **183**, 1187-1192,  
810 doi:10.1164/rccm.201008-1220OC (2011).
- 811 63 Suda, M. *et al.* Senolytic vaccination improves normal and pathological age-related  
812 phenotypes and increases lifespan in progeroid mice. *Nat Aging* **1**, 1117-1126,  
813 doi:10.1038/s43587-021-00151-2 (2021).
- 814 64 Capone, E., Iacobelli, S. & Sala, G. Role of galectin 3 binding protein in cancer  
815 progression: a potential novel therapeutic target. *J Transl Med* **19**, 405,  
816 doi:10.1186/s12967-021-03085-w (2021).
- 817 65 Luo, M. *et al.* LGALS3BP: A Potential Plasma Biomarker Associated with Diagnosis and  
818 Prognosis in Patients with Sepsis. *Infect Drug Resist* **14**, 2863-2871,  
819 doi:10.2147/IDR.S316402 (2021).
- 820 66 Pham, T. V., Henneman, A. A. & Jimenez, C. R. iq: an R package to estimate relative  
821 protein abundances from ion quantification in DIA-MS-based proteomics. *Bioinformatics*  
822 **36**, 2611-2613, doi:10.1093/bioinformatics/btz961 (2020).
- 823 67 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing  
824 and microarray studies. *Nucleic Acids Res* **43**, e47, doi:10.1093/nar/gkv007 (2015).
- 825 68 Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R Package for Comparing  
826 Biological Themes Among Gene Clusters. *OMICS: A Journal of Integrative Biology* **16**,  
827 284-287, doi:10.1089/omi.2011.0118 (2012).
- 828 69 Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.  
829 *The Innovation* **2**, 100141, doi:<https://doi.org/10.1016/j.xinn.2021.100141> (2021).
- 830 70 Shock, N. W. *Normal human aging : the Baltimore longitudinal study of aging*. (U.S.  
831 Dept. of Health and Human Services, Public Health Service, National Institutes of  
832 Health, National Institute on Aging, Gerontology Research Center, 1984).
- 833 71 Ferrucci, L. The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey  
834 and plans for the future. *J Gerontol A Biol Sci Med Sci* **63**, 1416-1419,  
835 doi:10.1093/gerona/63.12.1416 (2008).
- 836 72 Schrack, J. A. *et al.* Assessing the "physical cliff": detailed quantification of age-related  
837 differences in daily patterns of physical activity. *J Gerontol A Biol Sci Med Sci* **69**, 973-  
838 979, doi:10.1093/gerona/glt199 (2014).
- 839 73 Ferrucci, L. *et al.* Subsystems contributing to the decline in ability to walk: bridging the  
840 gap between epidemiology and geriatric practice in the InCHIANTI study. *J Am Geriatr*  
841 *Soc* **48**, 1618-1625, doi:10.1111/j.1532-5415.2000.tb03873.x (2000).
- 842 74 Candia, J. A.-O. *et al.* Assessment of Variability in the SOMAscan Assay. *Scientific*  
843 *Reports* **7**, 2045-2322 (2017).



844 75 Duggan, M. R. *et al.* Proteome-wide analysis identifies plasma immune regulators of  
845 amyloid-beta progression. *Brain Behav Immun* **120**, 604-619,  
846 doi:10.1016/j.bbi.2024.07.002 (2024).  
847 76 Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear  
848 Models via Coordinate Descent. *J Stat Softw* **33**, 1-22 (2010).  
849  
850

851 **FIGURE LEGENDS**

852

853 **Fig. 1 | Workflow for identification of SASP signatures from the aging plasma proteome. a,**

854 An in vitro model of senescent monocytes was developed by exposing THP-1 cells to IR and  
855 measuring senescence markers. Further quantitative mass spectrometry proteomics was  
856 performed on the secretome of these cells using the automated nanoparticle processing and  
857 digestion platform, Proteograph. Age association of the differentially secreted proteins was  
858 evaluated using proteomic and phenotypic data from the BLSA and InCHIANTI aging cohorts. **b,**  
859 The analysis pipeline used DIA-NN to identify monocyte secretome followed by filtering out the  
860 bovine and shared peptides. Peptide quantities from each nanoparticle was rolled up to proteins  
861 to determine the differentially expressed proteins.

862

863 **Fig. 2 | Establishing an IR-induced model of senescence in THP-1 monocytes. a,**

864 Representative fluorescence microscopy images from Edu incorporation assay and, **b,**  
865 corresponding quantification bar plots indicating reduced cellular incorporation of Edu by THP-1  
866 cells 7 days after IR exposure. **c,** Bar plots showing increased expression of known senescence  
867 markers and, **d,** elevated SPiDER  $\beta$ -gal confirming induction of senescence in IR treated THP-1  
868 cells. \* p-value < 0.05, \*\* p-value < 0.01, \*\*\* p-value < 0.001.

869

870 **Fig. 3 | Monocyte SASP is Associated with Age in the BLSA. a,** Principal Component

871 Analysis (PCA) of Neat samples (protein level). **b,** PCA of 6 NP samples (protein level). **c,** PCA  
872 of 14 NP samples (protein levels). For all PCA, only proteins present in all samples were used.  
873 **d,** Monocyte SASP were identified using nanoparticle processing on the Proteograph. **e,** The  
874 top 200 differentially expressed proteins were used for ontology analysis (p-value < 0.05, q-  
875 value < 0.1, Biological Process). **f,** Overlap between monocyte and fibroblast SASP. **g,** Ontology  
876 analysis of overlapping SASP proteins between monocytes and fibroblasts.

877

878 **Fig. 4 | Elastic Net Modeling Using SASP of Clinical Traits in the BLSA. a,** 1550 Monocyte

879 SASP are detected in the BLSA 7k SomaScan. **b,** Elastic Net models were trained on 80% of the  
880 BLSA cohort and used to predict clinical traits of the remaining 20%. Spearman correlations are  
881 shown between the predicted and observed values in the test set for each clinical trait. **c,** Elastic  
882 Net modeling was used for feature selection, and the number of Elastic Net Selected Proteins  
883 (ENSPs) implicated in each clinical trait are shown. **c,** ROC plot comparing the predictive potential  
884 (80% train, 20% test) of ENSPs positively associated with BMI to predict obesity with control-only

885 models, showing that ENSPs seem to provide additional predictive potential beyond age and  
886 other controls alone.

887  
888 **Fig. 5 | Modeling of the fat content in BLSA using SASP candidates. a,** Elastic Net models  
889 were trained on 80% of the BLSA cohort and used to predict clinical traits of the remaining 20%.  
890 Spearman correlations are shown between the predicted and observed values of the test set for  
891 each clinical trait. **b,** Elastic Net modeling was used for feature selection, and the number of  
892 Elastic Net Selected Proteins (ENSPs) implicated in each clinical trait are shown. **c,** ROC plot  
893 comparing the predictive potential (80% train, 20% test) of ENSPs positively associated with BMI  
894 to predict obesity with control-only models, showing that ENSPs seem to provide additional  
895 predictive potential beyond age and other controls alone. **d,** The correlation between observed  
896 waist size and that predicted by Elastic Net Modeling (80% train, 20% test).

897  
898 **Fig. 6 | SASP-based associations show robust replication in the InCHIANTI aging study. a,**  
899 220 monocyte SASP were detected in both the BLSA (7k SomaScan) and InCHIANTI (1.3k  
900 SomaScan). Elastic Net modeling was used for feature selection in both Inchianti and BLSA, and  
901 linear models were constructed using only proteins selected in both studies for each trait.  
902 Spearman's correlation of predicted values of linear models trained on the BLSA and observed  
903 values in InCHIANTI are shown on the x-axis, and Spearman's correlation of predicted values of  
904 linear models trained on InCHIANTI and observed values in the BLSA are shown on the y-axis **b,**  
905 Binomial models were trained either using controls (age, sex) or controls + ENSPs in BLSA, then  
906 used to predict obesity in Inchianti.

907  
908 **Fig. 7 | A high-impact SASP panel robustly predicts multiple clinical traits a,** For a 14-trait  
909 panel, proteins were ranked by the number of features for which they were selected via Elastic  
910 Net in the BLSA, and the most frequently selected proteins are shown with their cross-trait  
911 importance on the x-axis. Only proteins that were positively associated with negative traits such  
912 as BMI and CRP, and those that were inversely associated with positive traits such as mobility  
913 were selected. Stars indicate those that were also detected in InCHIANTI. **b,** Linear models were  
914 trained on 80% of the BLSA cohort and used to predict clinical traits in the remaining 20%.  
915 Spearman's correlation between the predicted and observed test values are shown. **c,** Linear  
916 models were trained on 80% of the InCHIANTI cohort and used to predict clinical traits in the  
917 remaining 20%. Spearman's correlation between the predicted and observed test values are  
918 shown. **d,** Principal Component Analysis was used to condense the high-impact panel into a

919 composite senescence burden score in the BLSA. Principal Component 1 was used to represent  
920 an eigengene for the high impact panel. With the BLSA cohort ranked from low to moderate to  
921 high senescence burden, linear trait trends reveal that positive traits HDL and Walking Pace show  
922 a negative trend, while negative traits BMI and CRP show a positive trend.

923

924


925

	All	20 to 40	40 to 60	60 to 70	80+	N
Count	1330	70	256	736	268	
age	67.8 (14.1)	33 (4.6)	51.7 (6)	70.8 (5.4)	84 (3.2)	
Female Percent	52.3	54.3	56.6	51.6	49.3	
eGFR	81.4 (17.7)	106.2 (12.4)	94.4 (13.2)	77.1 (14.5)	67.2 (12.8)	1062
BMI	26.9 (4.6)	25.1 (4.8)	27.1 (4.8)	27.5 (4.8)	25.6 (3.3)	1323
Waist_Size	88.5 (13.1)	82.1 (12.1)	86.2 (12.7)	90.1 (13.5)	88.1 (11.5)	1283
LDL	106.4 (31.9)	95.2 (28.1)	111.3 (31.2)	106.5 (33)	103.3 (29)	1054
Triglycerides	99.7 (50.5)	88.6 (43.5)	98.6 (52.6)	102.5 (50.5)	96.1 (49.4)	1056
CRP	2.6 (4.4)	1.5 (2.1)	2 (3.1)	2.8 (4.3)	3.1 (6.2)	998
IL6	4.2 (3.5)	3.7 (3.5)	3.6 (2.5)	4.3 (3.5)	4.7 (4.6)	996
Fasting_Glucose	96.6 (13.6)	90.1 (6.9)	95.1 (11.5)	98.7 (15.4)	95 (10.9)	996
De_Fat_Trunk	13291.6 (6209.7)	10026.7 (5926.6)	13010.6 (6411)	14333.8 (6189.1)	11502.7 (5143.4)	1022
De_Fat_Body	26497.1 (10343.6)	21591.9 (10713.4)	26346.4 (10389)	28237.5 (10484.9)	22828.3 (7788.7)	1022
De_Fat_Arms	2589.9 (1078.8)	2069.5 (1025.4)	2582.5 (1110.2)	2752.1 (1097.8)	2264.5 (826.3)	1022
De_Fat_Legs	9724.2 (4091.7)	8729.7 (4340.5)	9880.8 (3818.4)	10222.8 (4344.1)	8217.9 (2916.6)	1022
CT_Abd_SubFat	27620.3 (12738.4)	25676.1 (18611.6)	27001.3 (12284.8)	29057 (13029.9)	23814.1 (9508.3)	711
CT_Abd_ViscFat	9922.2 (5654.7)	5408.9 (3678.7)	7888.2 (4615.1)	10761.3 (5847.2)	10559.9 (5447.7)	711
CT_Abd_ViscSubProp	0.4 (0.2)	0.2 (0.1)	0.3 (0.2)	0.4 (0.2)	0.5 (0.3)	653
CT_Thigh_SubFat	8389.1 (4539.1)	8094.1 (5255.4)	8510.6 (4324.1)	8846.6 (4737.3)	6832.2 (3458.5)	900
CT_Thigh_IMFat	1220.5 (509.8)	895.9 (489.6)	1174.8 (549.8)	1256.4 (489.2)	1306.5 (465.6)	898
Fat_Percent	35.3 (9.4)	29.5 (10.1)	34.3 (9.3)	37 (9.2)	33.6 (8.5)	1022
BP_Sys	122.9 (18.9)	110.5 (12.6)	118.1 (15.7)	124.2 (18.7)	130.4 (21.7)	902
BP_Dias	66 (9.4)	62.1 (7.1)	68.1 (9.3)	65.9 (9.6)	64.8 (8.6)	884
A1C	5.8 (0.6)	5.3 (0.4)	5.6 (0.6)	5.9 (0.7)	5.8 (0.3)	965
Chair_Stands_Pace_5	0.6 (0.2)	0.7 (0.2)	0.7 (0.2)	0.5 (0.2)	0.5 (0.2)	975
Chair_Stands_Pace_10	0.5 (0.2)	0.7 (0.2)	0.6 (0.2)	0.5 (0.2)	0.5 (0.1)	972
Usual_Gait_Speed	1.2 (0.2)	1.3 (0.2)	1.3 (0.2)	1.2 (0.2)	1.1 (0.2)	977
Rapid_Gait_Speed	1.8 (0.4)	2.1 (0.3)	2 (0.3)	1.8 (0.4)	1.6 (0.3)	978
Walk_Pace_400_Meter	1.6 (0.3)	1.8 (0.2)	1.7 (0.2)	1.6 (0.2)	1.3 (0.2)	929
HDL	61.4 (17.3)	60.1 (15.5)	60.8 (18.1)	61.3 (16.8)	63.1 (18.5)	1056


926

927 **Table 1. Demographic and clinical traits in the Baltimore Longitudinal Study of Aging. Data**  
 928 reported as mean (standard deviation).


929



**Fig. 1 | Workflow for identification of SASP signatures from the aging plasma proteome. a,** An in vitro model of senescent monocytes was developed by exposing THP-1 cells to IR and measuring senescence markers. Further quantitative mass spectrometry proteomics was performed on the secretome of these cells using the automated nanoparticle processing and digestion platform, Proteograph. Age association of the differentially secreted proteins was evaluated using proteomic and phenotypic data from the BLSA and InCHIANTI aging cohorts. **b,** The analysis pipeline used DIA-NN to identify monocyte secretome followed by filtering out the bovine and shared peptides. Peptide quantities from each nanoparticle was rolled up to proteins to determine the differentially expressed proteins.




**Fig. 2 | Establishing an IR-induced model of senescence in THP-1 monocytes.** **a**, Representative fluorescence microscopy images from Edu incorporation assay and, **b**, corresponding quantification bar plots indicating reduced cellular incorporation of Edu by THP-1 cells 7 days after IR exposure. **c**, Bar plots showing increased expression of known senescence markers and, **d**, elevated SPiDER β-gal confirming induction of senescence in IR treated THP-1 cells. \* p-value < 0.05, \*\* p-value < 0.01, \*\*\* p-value < 0.001.




**Fig. 3 | Monocyte SASP is Associated with Age in the BLSA.** **a**, Principal Component Analysis (PCA) of Neat samples (protein level). **b**, PCA of 6 NP samples (protein level). **c**, PCA of 14 NP samples (protein levels). For all PCA, only proteins present in all samples were used. **d**, Monocyte SASP were identified using nanoparticle processing on the Proteograph. **e**, The top 200 differentially expressed proteins were used for ontology analysis ( $p$ -value < 0.05,  $q$ -value < 0.1, Biological Process). **f**, Overlap between monocyte and fibroblast SASP. **g**, Ontology analysis of overlapping SASP proteins between monocytes and fibroblasts.







**Fig. 4 | Elastic Net Modeling Using SASP of Clinical Traits in the BLSA.** **a**, 1550 Monocyte SASP are detected in the BLSA 7k SomaScan. **b**, Elastic Net models were trained on 80% of the BLSA cohort and used to predict clinical traits of the remaining 20%. Spearman correlations are shown between the predicted and observed values in the test set for each clinical trait. **c**, Elastic Net modeling was used for feature selection, and the number of Elastic Net Selected Proteins (ENSPs) implicated in each clinical trait are shown. **d**, ROC plot comparing the predictive potential (80% train, 20% test) of ENSPs positively associated with BMI to predict obesity with control-only models, showing that ENSPs seem to provide additional predictive potential beyond age and other controls alone.



**Fig. 5 | Modeling of the fat content in BLSA using SASP candidates.** **a**, Elastic Net models were trained on 80% of the BLSA cohort and used to predict clinical traits of the remaining 20%. Spearman correlations are shown between the predicted and observed values of the test set for each clinical trait. **b**, Elastic Net modeling was used for feature selection, and the number of Elastic Net Selected Proteins (ENSPs) implicated in each clinical trait are shown. **c**, ROC plot comparing the predictive potential (80% train, 20% test) of ENSPs positively associated with BMI to predict obesity with control-only models, showing that ENSPs seem to provide additional predictive potential beyond age and other controls alone. **d**, The correlation between observed waist size and that predicted by Elastic Net Modeling (80% train, 20% test).



**Fig. 6 | SASP-based associations show robust replication in the InCHIANTI aging study. a,** 220 monocyte SASP were detected in both the BLSA (7k SomaScan) and InCHIANTI (1.3k SomaScan). Elastic Net modeling was used for feature selection in both Inchiанти and BLSA, and linear models were constructed using only proteins selected in both studies for each trait. Spearman's correlation of predicted values of linear models trained on the BLSA and observed values in InCHIANTI are shown on the x-axis, and Spearman's correlation of predicted values of linear models trained on InCHIANTI and observed values in the BLSA are shown on the y-axis **b,** Binomial models were trained either using controls (age, sex) or controls + ENSPs in BLSA, then used to predict obesity in Inchiанти.



**Fig. 7 | A high-impact SASP panel robustly predicts multiple clinical traits** **a**, For a 14-trait panel, proteins were ranked by the number of features for which they were selected via Elastic Net in the BLSA, and the most frequently selected proteins are shown with their cross-trait importance on the x-axis. Only proteins that were positively associated with negative traits such as BMI and CRP, and those that were inversely associated with positive traits such as mobility were selected. Stars indicate those that were also detected in InCHIANTI. **b**, Linear models were trained on 80% of the BLSA cohort and used to predict clinical traits in the remaining 20%. Spearman's correlation between the predicted and observed test values are shown. **c**, Linear models were trained on 80% of the InCHIANTI cohort and used to predict clinical traits in the remaining 20%. Spearman's correlation between the predicted and observed test values are shown. **d**, Principal Component Analysis was used to condense the high-impact panel into a composite senescence burden score in the BLSA. Principal Component 1 was used to represent an eigengene for the high impact panel. With the BLSA cohort ranked from low to moderate to high senescence burden, linear trait trends reveal that positive traits HDL and Walking Pace show a negative trend, while negative traits BMI and CRP show a positive trend.